; IRS, insulin response sequence (49) ; HNF-1, hepatic nuclear factor 1 (37, 57. 59) ; NF-1, nuclear factor 1 (57, 59. 62) ; CRE, cAMP response element (57. 65) ; and X. Y, and Z. unknown factors (59) . A retinoic acid response element also coincides with the 5'-most accessory factor (43) .
quences. Transgene expression can be assessed in numerous cell types as well as examined during both embryonic and fetal development.
This study was undertaken to determine whether distinct cell types utilize common or unique cis-acting elements to regulate transcription of the PEPCK gene. Because of the rich diversity of tissues that express and uniquely regulate the PEPCK gene, we chose to use PEPCK-human growth hormone (hGH) fusion genes in transgenic mice to map the cis-acting elements controlling its tissue-or cell-specific expression. Indeed, transgenic mice bearing hGH reporter genes have been used successfully to map and characterize cis-acting elements that regulate genes expressed in single cell types, such as the genes encoding elastase, protamine, and albumin (9, 56, 67) , and genes expressed in multiple cell types, such as those encoding metallothionein, transferrin, and fatty acid-binding protein (28, 32, 34) , to name a few. We tested five PEPCK promoter fragments with 5' deletion endpoints of -2088, -888, -600, -402, and -207 bp. To ascertain the fidelity of transgene expression, we also chose to quantitate both PEPCK mRNA and hGH mRNA molecules per cell by a solution hybridization assay. We were thus able to identify PEPCK DNA sequences that recapitulated wild-type levels of transgene expression in most tissues. Our results indicate that different cell types use distinct cis-acting elements to direct expression of the PEPCK gene.
MATERIALS AND METHODS
Construction of PEPCK-hGH fusion genes and production of transgenic mice. Five rat PEPCK-hGH fusion genes that contained various amounts of PEPCK 5' flanking DNA were made (Fig. IA) . The PEPCK genomic DNAs were derived from subclones of XPC 112 (4) . A BglII site in the 5' untranslated region of the rat PEPCK gene at +69 in the first exon served as a common 3' endpoint for linking the PEPCK DNA fragments to a BamHI site in the first exon of the hGH gene. The largest PEPCK-hGH fusion gene contained 2,088 bp of PEPCK 5' flanking DNA and was constructed by restriction with Sacl, blunting of the 3' overhang with T4 DNA polymerase, and addition of a Sall linker. After digestion with BglII and Sall, the resulting DNA fragment was ligated into the Sall and BamHI sites of pOGH (64) . The constructs containing 888, 402, and 207 bp of 5' flanking PEPCK DNA were derived from a series of PEPCK deletion mutants generated with Bal 31 exonuclease, ligated to a Sall linker, and subcloned into pPLFCAT (57) . The (12) . The DNA concentration was measured and diluted to 3 ng/,l for microinjection. About 2 pl of the DNA solution was microinjected into the pronuclei of fertilized (C57BL/6 x SJL)F2 hybrid mouse eggs which were cultured to the two-cell stage. Two-cell embryos were transferred to day 1 pseudopregnant recipients as previously described (10) . Transgenic animals were identified by dot blot analysis of tail nucleic acids, using a 32P-labeled hGH cDNA probe (50) .
Transgenic mouse lines. Several lines of transgenic mice were established during the -course of this study. Two lines were particularly important for parts of this study ( Fig. 3 to  7 ; Tables 1 and 2) ; they were derived from founder mice 50-3 and 99-3, which bore the -2088 (four copies per haploid genome) and the -402 (eight copies per haploid genome) PEPCK-hGH transgenes, respectively. These particular lines were used because they typify the overall expression patterns of their respective transgenes (shown in Fig. 4 and described in Results). Because of the impaired fertility resulting from hGH expression (3, 29) , established lines were maintained through ovarian transplants (61 Measurement of PEPCK mRNA and hGH mRNA abundance. Total nucleic acids were isolated by homogenizing 50 to 100 mg of tissue in 4 ml of 1% sodium dodecyl sulfate-i mM EDTA-10 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES; pH 7.5) (SEH) buffer with 100 ,ug of proteinase K per ml, incubating the extract at 45°C, and then isolating total nucleic acids by phenol-chloroform extraction and ethanol precipitation (20) . The (Fig. 1A) . These PEPCK-hGH fusion genes contained PEPCK DNA fragments with 5' endpoints of -2088, -888, -600, -402, and -207 bp. In all five constructs, the PEPCK DNA was fused to the hGH gene at the BglII site (+69) of PEPCK. For reference, Fig. lB shows the three proximal deletion endpoints superimposed on a map of known cis-acting elements that have been identified by transfection and DNA-binding assays. The PEPCK-hGH fusion genes were separated from plasmid DNA and used to produce 9 to 16 founder animals per construct. A total of 49 transgenic founder mice were generated; 37 of these expressed the transgenes in one or more tissues. Of the mice identified as transgenic, 75, 73, 73, 54 , and 0% of the -2088, -888, -600, -402, and -207 constructs, respectively, grew to approximately twice the size of their nontransgenic littermates and displayed a phenotype typical of transgenic mice expressing hGH (51, 52) . The number of transgenes integrated into the DNA of each founder mouse varied from 1 to 500 copies per cell; however, no correlation was observed between copy number and expression of hGH mRNA (unpublished data).
As (Fig. 2) . PEPCK mRNA was always detectable in liver, kidney, white fat, brown fat, ileum, jejunum, and colon but was detectable in the hearts of only three of five mice and in skeletal muscle of only two of five mice. PEPCK mRNA was not detectable in lung, gonads, spleen, or brain.
To determine whether expression of hGH had an effect on PEPCK gene expression (which would render hGH inappropriate as a reporter gene), PEPCK mRNA levels were measured in liver, kidney, white fat, and brown fat in five transgenic mice. The PEPCK mRNA levels (615 ± 119, 435 + 106, 176 + 39, and 780 ± 147 molecules per cell in liver, kidney, white fat, and brown fat, respectively) in these transgenic mice were not significantly different from those in control mice. These five transgenic mice had high serum hGH levels (data not shown), exhibited enhanced growth, and had hepatic hGH mRNA levels in excess of 4,000 molecules per cell. Thus, elevated serum hGH did not affect expression of the PEPCK gene, and therefore the hGH gene appears to be an appropriate reporter.
Expression of the -2088 PEPCK-hGH transgene is similar to PEPCK expression in most but not all tissues. Expression of the construct bearing the longest piece of PEPCK DNA (-2088) was examined first by Northern blot analysis of RNA isolated from 15 tissues. Figure 3 shows a representative blot using tissues from a mouse of the 50-3 lineage bearing the -2088 PEPCK-hGH transgene. The blot was probed sequentially for PEPCK and hGH mRNAs in order to compare transgene expression with that of the endogenous PEPCK gene. PEPCK mRNA was detected in liver, kidney, ovarian white fat, suprascapular brown fat, sublingual gland, skeletal muscle, jejunum, colon, and ileum but not in spleen, brain, stomach, lung, heart, or pancreas of this mouse. hGH mRNA was detected in all of the tissues that expressed PEPCK mRNA and additionally in stomach, lung, and heart. This result indicated that the essential tissuespecific control elements are present in the -2088 to +69 bp region, as there was good qualitative correspondence between tissues that express PEPCK and those that express the transgene (except for stomach, lung, and heart). (4, 36) . Second, the site of transgene integration, which is random, can have profound effects on the level of its expression as a result of endogenous regulatory elements near the integration site (52) . Third, PEPCK is localized in minor cell types in some tissues such as lung and skeletal muscle (75) ; hence, PEPCK mRNA levels measured in whole tissue extracts of lung and skeletal muscle may be at or below the detection limit, whereas hGH mRNA is not. Finally, additional cis-acting elements involved in control of the PEPCK gene might lie outside of the -2088 to +69 bp region tested.
To control for the effects of transgene integration site, expression of the -2088 PEPCK-hGH transgene was quantified in 10 transgenic mice in a solution hybridization assay. As shown in Fig. 4 , a total of 10 founders (or their offspring) gave an overall pattern of expression from the -2088 transgene that was qualitatively similar to that shown in the Northern analysis (Fig. 3) . In addition, low levels of hGH mRNA were detected in heart and skeletal muscle of several mice. Because no two mice are likely to have the same integration site, the average level of transgene expression determined from multiple mice likely reflects the cis-acting elements present within the transgene.
We also determined whether expression of the -2088 transgene was quantitatively correct in the tissues surveyed. If all of the cis-acting elements that control PEPCK expression are included in the -2088 transgene, then the expected hGH/PEPCK mRNA ratio in a given tissue should be directly proportional to the ratio of their half-lives. The reported half-lives suggest that hGH mRNA is approximately an order of magnitude more stable than PEPCK mRNA (4, 36), and we made the initial assumption that this ratio would hold constant for all transgenic mouse tissues that express these two mRNA species. Transgene expression in liver, white fat, ileum, jejunum, skeletal muscle, and possibly heart and colon (Fig. 4) were close to the predicted values of 4,450 ± 890, 1,070 ± 420, 30 ± 10, 50 ± 10, 30 + 20, 90 ± 40, and 70 ± 30 molecules per cell, respectively. In contrast, expression in kidney (153 ± 100) and brown fat (300 ± 160) was significantly lower than expected (2,250 ± 430 and 3,740 ± 1,290, respectively), and expression in lung (50 ± 20) and gonad (30 ± 30) was higher than expected (0 for both).
Cellular localization of hGH. Immunohistochemistry was used to analyze the precise cellular distribution of transgene expression within tissues surveyed for hGH mRNA. Animals used for these studies were second-and third-generation progeny of the 50-3 line (-2088 transgene). hGH immunoreactivity was evident in liver, kidney, white adipose tissue, brown adipose tissue, ileum, jejunum, colon, lung, vagina, and sublingual gland ( Fig. 5 and 6 ). hGH-specific staining was unambiguous in these 10 tissues, as there was no staining when nonimmune serum was used as a control (data not shown). In liver ( Fig. 5A and B), hGH staining was restricted to hepatocytes in the same pattern as that for PEPCK (2, 75): a decreasing gradient of hGH immunoreactivity from the periportal to the perivenous parenchymal cells. A gradient of expression was also found in the renal cortex, where hGH was localized to the proximal tubule epithelia of the kidney cortex, with decreasing reactivity in the medulla (Fig. SC and D) . This staining pattern is restricted to the same cell type and has the same gradient as does renal PEPCK (75) . Staining of hGH in the ileum, jejunum, and colon was localized to the epithelial cells lining the villi; staining was more intense in the ileum than in the jejunum and colon ( Fig. SE to H ; Fig. 6A and B). There was a gradient of expression that was highest toward the tips of the villi and decreased toward their bases. This same pattern occurs with immunohistochemical staining for PEPCK (75) . However, the strict epithelial localization of hGH was in contrast to the staining of PEPCK, which is localized to both epithelial cells and smooth muscle cells along the entire digestive tract (75) . Both white and brown adipose tissue and ductal epithelial cells in sublingual gland had identical staining patterns with anti-PEPCK (75) and anti-hGH (Fig. 6E, F , and H). These observations suggest that the region of PEPCK DNA between -2088 and +69 bp contain cis-acting elements that direct cell-specific expression of PEPCK in hepatocytes, proximal tubular epithelia of the renal cortex, small intestinal epithelium, colonic epithelium, and white and brown adipocytes. Finally, low levels of immunoreactive hGH were localized to the vascular smooth muscle of the lung and the muscular wall of the vagina in the -2088 transgenic mice (Fig. 6C, D , and G). This finding suggests the presence of cell-specific cis-acting elements in these tissues, as PEPCK immunoreactivity is also found in these same cell types (75) . We were unable to confirm the cellular localization of hGH (in excess of background) in adrenal gland, bladder, brain, heart, stomach, pancreas, skeletal muscle, and parotid gland, tissues which exhibit hGH mRNA or PEPCK immunoreactivity (75) .
Low-resolution mapping of tissue-specific cis-acting elements by deletion analysis. The tissue-specific expression of four truncated PEPCK-hGH constructs was examined in transgenic mice to more precisely map the locations of sequences directing multitissue expression of the PEPCK VOL. 12, 1992 on (9) of hGH in the ovary, which occurred in three of five -2088 females, was not detected in any of the eight female -888 mice. Lastly, average expression of the transgene in liver, (6) ileum, jejunum, colon, and lung was reduced about fivefold 1(6) by deletion to -888 bp; however, these decreases were not (Fig. 4) . While expres- 
-600 bp region might contain a weak inhibitory element that 6)~~~~~~~~9) (6) (6) (6) functions in brown fat and colon.
O(6)(6)(6) (10) finding suggests that the -600 to -402 bp region of PEPCK DNA contains cis-acting elements that are important for (10) quantitative expression of PEPCK in liver; they are not, 60 T (3) however, essential for liver-specific expression. cis-acting (9) elements to which hepatic accessory factors 1 and 2 bind are (6) located in this region (Fig. iB) Truncation of PEPCK to -207 bp had minimal effects compared with the -402 construct; only two tissues, liver and kidney, exhibited significant changes in transgene expression. The content of hGH mRNA decreased fourfold in liver and threefold in kidney. This decrease is most evident when viewed in terms of the number of mice expressing hGH mRNA: while all of six and four of six -402 mice had detectable levels of hGH mRNA in liver and kidney, respectively, only three of nine -207 mice had detectable hGH mRNA in either liver or kidney.
Correct developmental expression of the -2088 transgene occurs in liver but not kidney. Developmental expression of the PEPCK gene in liver is induced at parturition in response to changes in the insulin/glucagon ratio (23); however, it can be hormonally induced 6 days prior to birth. It seems likely that the correct ontogenic expression of PEPCK requires the interaction of both differentiation-specific trans-acting factors with hormone responsive cis-acting elements. Thus, an additional test for the presence of essential tissue-specific cis-acting elements in a transgene is to determine whether the pattern of developmental activation is correct. We assayed PEPCK and hGH mRNAs in fetal and neonatal mice of the 50-3 line to determine whether the -2088 PEPCKhGH transgene directed the correct pattern of developmental expression in liver and kidney (Fig. 7) . As expected, the levels of hepatic PEPCK mRNA were low during the fetal period, increased at parturition, and remained constant thereafter. Expression of the transgene in liver followed a very similar developmental profile. There was an abrupt induction of hGH mRNA at birth, with averages of 350 and 1,100 molecules per cell at days 1 and 7, respectively. The somewhat delayed induction and higher levels of hGH mRNA (compared with PEPCK mRNA) are likely explained by the greater stability of hGH mRNA. Half-lives of greater than 1 day for hGH mRNA and much less than 1 day for PEPCK mRNA can be inferred from the kinetics of induction in Fig. 7A . The similarity between PEPCK gene activation and transgene activation during liver development suggests that the region between -2088 and +69 bp contains elements essential for liver-specific expression (as well as responsiveness to insulin and glucagon).
In contrast to the liver, the developmental pattern of expression from the -2088 transgene in kidney did not correspond with expression of the PEPCK gene. As shown in Fig. 7B , the hGH mRNA level was approximately 24 molecules per cell 4 days prior to parturition and increased to a peak of approximately 210 molecules per cell at day -1. There was a subsequent decline in hGH mRNA so that adult levels of approximately 40 molecules per cell were attained by day 7. In contrast, PEPCK mRNA remained extremely low during the fetal and early neonatal period and showed a marked induction between days 1 and 7. The abnormal level of transgene expression in kidney versus liver in several mice ( Fig. 4A and B) suggests that this pattern is not unique to the 50-3 lineage and that additional control elements outside of the -2088 to +69 bp region are required to achieve both the correct magnitude and correct developmental pattern of PEPCK expression in kidney. Regulation of transgene expression by glucocorticoids. Transcription of the PEPCK gene responds to glucocorticoid hormones in a tissue-specific pattern; it is induced in liver and kidney and repressed in adipose tissue (48) . The elements necessary for response to glucocorticoids in liver are thought to span a region of -110 bp between -455 and -350 bp (35) (Fig. 1B) . The -2088 transgene thus contains an intact glucocorticoid response unit and should be induced by dexamethasone, whereas the -402 transgene should be unresponsive. We tested the response of the -2088 and -402 transgenes to dexamethasone in mice of the 50-3 and 99-3 lines, respectively (Table 1) . Following dexamethasone treatment of the -2088 mice, PEPCK mRNA levels in the liver increased twofold and hGH mRNA showed a similar threefold increase. In kidney, PEPCK mRNA increased threefold, while hGH mRNA increased fivefold. The induction of PEPCK expression in jejunum was of greater magnitude than that in liver, with a fivefold increase in PEPCK mRNA from 85 to 413 molecules per cell. At the corresponding time, hGH mRNA increased sevenfold. In adipose tissue, dexamethasone caused a fivefold decrease in PEPCK mRNA, while hGH mRNA did not exhibit any significant change (Table 1) . Dexamethasone treatment of the -402 mice did not result in any changes in hepatic, renal, or FIG. 6 . Immunocytochemical localization of hGH in colon, lung, brown fat, white fat, vagina, and sublingual gland. Additional organs were prepared from the mouse used for Fig. 3 and 5 ; experimental details are described in the legend to adipose tissue hGH mRNA concentrations. The effects of dexamethasone on transgene expression in jejunum could not be assessed, as hGH mRNA levels were below the sensitivity of the assay. These results suggest that sequences required for glucocorticoid responsiveness in liver, kidney, and small intestine are located between -2088 and -402 bp. In contrast, either the inhibitory element(s) required for dexamethasone response in adipose tissue is absent from the -2088 and -402 constructs or the regulation of the fusion genes in this tissue is affected by the site of transgene integration.
Regulation of transgene expression by diet. Expression of the PEPCK gene in liver is reciprocally regulated by plasma glucagon and insulin levels (23) . While both the -2088 and -402 transgenes contain a cAMP response element, the -402 transgene lacks an insulin response sequence (Fig.  1B) , and so differences in the dietary responsiveness of the two constructs were expected. To test this prediction, we compared the effects of feeding animals either a highcarbohydrate diet or a high-protein diet on liver and kidney PEPCK and hGH mRNAs ( Table 2 ). In the -2088 mice, liver PEPCK mRNA levels were approximately twofold higher in mice fed a high-protein diet than in mice fed the high-carbohydrate diet, and in the same animals hGH mRNA levels increased approximately fourfold. In kidney, PEPCK mRNA and hGH mRNA were induced about 3-and 11-fold, respectively, by feeding the mice a diet high in protein. The effect of these two diets on PEPCK mRNA in liver and kidney of the -402 mice was similar to that in the -2088 mice. However, the response of the transgene in liver was far more dramatic, as there was a >13-fold (467 to 6,149 molecules per cell) increase in protein-fed versus carbohydrate-fed mice. These results suggest that diet-responsive elements (probably cAMP and/or insulin response elements) are located between -402 and +69 bp and that sequences between -402 and -2088 bp probably modulate the effects of the more promoter-proximal elements. Indeed, O'Brien et al. (49) have shown that there is an additional, previously unmapped insulin responsive sequence in the promoterproximal region between -402 and +69 bp. DISCUSSION Study of the PEPCK gene provides a unique model of genes expressed in multiple tissues and regulated by numerous hormones, environmental factors, and cell-cell interactions (5, 7, 11, 15, 24, 43, 45, 54, 68, 69, 71, 72) . For this study, we sought to determine whether multiple tissues, especially liver, kidney, and fat, utilize common or unique tissue-specific cis-acting elements to direct and regulate the PEPCK gene. Since the only available cell lines that express PEPCK were hepatoma cells and adipoblasts, we used transgenic mice to assess expression of PEPCK fusion genes in diverse cell types and during development. A total of 49 transgenic founder mice from a series of five PEPCK-hGH fusion genes were made; 37 of these mice expressed the PEPCK/hGH transgene in one or more tissues. Our results indicate that deletion of various upstream regions of PEPCK DNA had differential effects on transgene expression in liver, kidney, and fat as well as in various other tissues. Although this finding does not rule out the possibility that different cell types share some common cis-acting elements, it does strongly suggest that different cell types must utilize different cis-acting elements to direct and regulate the PEPCK gene.
Control Fig. 1B ) have been shown to interact with cis-acting elements upstream of the PEPCK promoter in liver. Both CREB and NF-1 are present in a variety of tissues and thus probably support transcription in numerous tissues (57, 59, 69) . However, since both CREB and NF-1 are families of transcription factors, various members of each family could have functional differences and tissue-specific distributions (25, 62) . Thus, neither should be ruled out as contributors to tissue-specific expression. C/EBP binds a total of four sites upstream of the PEPCK promoter (53) , has an expression pattern similar to that of PEPCK (liver, kidney, fat, and intestine but not spleen, brain, or testis), and appears in liver just before birth when PEPCK is activated (8, 69) . Thus, C/EBP could participate in driving PEPCK expression in hepatocytes as well as intestine, fat, kidney, and lung. HNF-1 expression is restricted to liver, kidney, and intestine (37) . In liver, it binds to the upstream regions of several liver-specific genes such as the fibrinogen and al-antitrypsin genes (19) . The observation that a -174 to +69 bp PEPCK-bovine growth hormone chimera is completely inactive in transgenic mice (44) may be particularly meaningful when compared with the data for our transgene. Specifically, the only obvious difference between our -207 transgene and the -174 transgene is an HNF-1 binding site (Fig. 1B) . Thus, HNF-1 could act alone or in combination with another, more proximal factor(s) such as CREB, NF-1, C/EBP, or the factor that binds at site X (indicated in Fig. 1B ) to impart basal liver-specific expression. Indeed, X could be a binding site for HNF-3, another hepatocyte-enriched trans-acting factor, as 11 of 14 bases from -156 to -143 are identical to bases in the sequence of a known HNF-3 binding site (GATTATTGACT TAG) (73) .
Our observations along with published reports clearly show that additional elements upstream of position -207 are involved in expression of PEPCK in hepatocytes. These upstream elements are also candidates for control of liverspecific expression, though they may function only in hormonal regulation and nonspecific enhancement. The region between -402 and -207 bp includes two glucocorticoid receptor binding sites, three C/EBP binding sites, and at least two binding sites for unidentified transcription factors.
The third domain (from -600 to -402 bp) contains the two glucocorticoid response unit accessory elements, a retinoic acid response element, and the insulin response sequence indicated in Fig. 1B (35, 43, 49 ). We do not know whether the elements in this third domain function as liver-specific elements, though it is interesting to note that the accessory factor region (accessory factors 1 and 2) contains three HNF-4/LF-A1 binding site homologies [(G/T)GC(AIT)A(AI G)G(G/T)(T/C)CA(T/C)J spaced so that their orientation would be on the same face of the double helix (69) . HNF-4/ LF-A1 is a liver-specific transcription factor associated with several liver-specific genes, including the al-antitrypsin, apolipoprotein CIII, and haptoglobin genes (31, 41, 66 Tissue-specific regulation of PEPCK expression by glucocorticoids and diet. In view of the foregoing evidence for distinct tissue-specific control elements, we reasoned that there may also be tissue-specific responses to diet and glucocorticoids. Therefore, we tested the effects of dexamethasone and diet on the -2088 and the -402 transgenes. In agreement with Imai et al. (35) , who showed that the glucocorticoid response unit consists of the two accessory factor elements plus the two glucocorticoid receptor binding sites (Fig. 1B) , the -2088 transgene was induced by dexamethasone in the liver, whereas the -402 transgene did not respond. A similar response pattern occurred in kidney, suggesting that the same stimulatory glucocorticoid response unit functions in both organs. In contrast, dexamethasone treatment in fat did not elicit a response by either transgene, whereas PEPCK mRNA levels decreased. The simplest explanation for this observation is that adipocytes utilize a unique fat-specific cis-acting element for this inhibitory response.
The -2088 and -402 transgenes displayed interesting 
